A new patch from DBV Technologies, a French company, could cure peanut allergies in large numbers, according to an article on fastcompany.com, which notes that anywhere from 1 to 8 percent of children now run the risk of peanut allergies.

The Viaskin patch is still involved in clinical trials, but it should be on the U.S. market by 2018, says Pierre-Henri Benhamou, CEO of DBV Technologies.

“It will be three years for peanut allergy, but at the end patients will be able to take in every kind of peanut. There will no more need to restrict their diet,” Benhamou told fastcompany.com.

Read full story here.